Zhao, Min <br/><br/>
Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration.  [electronic resource] 

 -  Nature communications  01 2019 
 - 369 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2041-1723 
<br/><br/><label>Standard No.: </label>10.1038/s41467-018-08125-6  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Angiogenesis Inhibitors--therapeutic use<br/>Animals<br/>Choroid--drug effects<br/>Choroidal Neovascularization--drug therapy<br/>Drug Compounding--methods<br/>Female<br/>Gene Expression<br/>Humans<br/>Intravitreal Injections<br/>Macular Degeneration--drug therapy<br/>Male<br/>Mice<br/>Mice, Transgenic<br/>Microspheres<br/>Mineralocorticoid Receptor Antagonists--therapeutic use<br/>Pilot Projects<br/>Prospective Studies<br/>Ranibizumab--therapeutic use<br/>Rats, Long-Evans<br/>Receptors, Mineralocorticoid--genetics<br/>Receptors, Vascular Endothelial Growth Factor--therapeutic use<br/>Recombinant Fusion Proteins--therapeutic use<br/>Spironolactone--therapeutic use<br/>Treatment Outcome<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors